The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The Effects of Early RA Treatment on CVD

The Effects of Early RA Treatment on CVD

February 19, 2019 • By Carina Stanton

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In a first randomized controlled trial-derived longitudinal study, researchers found that a disease-modifying anti-rheumatic drug (DMARD) and etanercept, a biologic DMARD (bDMARD), in treatment-naive, early rheumatoid arthritis (RA) patients free of known cardiovascular disease (CVD) reduced vascular function abnormalities measured by cardiac MRI. Findings from the Coronary Artery Disease Evaluation in Rheumatoid Arthritis (CADERA) study suggest this treatment strategy may influence aortic distensibility more than disease activity and that there may be a treatment advantage of etanercept+ methotrexate over methotrexate with or without additional conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs).1

You Might Also Like
  • Cardiovascular Abnormalities Seen in Treatment-Naive RA Patients
  • Effects of Obesity on Sustained Remission in Early RA
  • Higher Tocilizumab Dose Plus Methotrexate Best for Early RA
Also By This Author
  • ACR Opposes UnitedHealthCare’s Move to End Consultation Reimbursement

This study highlights the importance of identifying patients at risk of CVD early as a management strategy, according to Maya H. Buch, MD, PhD, co-investigator of the study and a rheumatologist at the Leeds Institute of Rheumatic and Musculoskeletal Medicine, U.K. Dr. Buch reported these initial findings at the 2018 ACR/ARHP Annual Meeting in Chicago. “These findings also confirm RA therapy, without specific CVD therapy, improves CVD changes, thus, implying atherosclerosis comprises inflammation that is amenable to RA therapy.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Buch says, “If the suggestion of differential benefit between the two treatment strategies is proved in the future, this would expand the remit of personalized/stratified therapy, [indicating] we should be tailoring therapy [not just] to traditional outcomes of RA, but also [to] CVD.”

The CADERA Study
In this phase of the CADERA study, 80 patients with early RA (defined as symptomatic for less than 12 months) who had no prior RA therapy and no history of CVD were randomized into two groups. Group 1 received first-line etanercept, a TNF inhibitor (TNFi) bDMARD, plus methotrexate. Group 2 received methotrexate in a treat-to-target planned escalation to a triple, conventional synthetic (cs) DMARD (methotrexate, sulphasalasine, and hydroxychloroquine). At Week 24, patients in Group 2 who failed to achieve clinical remission were switched to etanercept plus methotrexate (referred to as escalated patients).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

At Week 48, the etanercept was stopped in both groups and standard-of-care treatment comprising csDMARD with or without bDMARD as per the National Institute for Health and Care Excellence (NICE)  and local guidance was maintained with observation up to Week 96. The changes in aortic distensibility value from baseline were then evaluated.

All patients, including patients from Group 2, demonstrated a significant reduction in mean aortic distensibility from baseline through Year 1, with these results maintained at Year 2.

Previously reported work from the CADERA study includes study protocol and demonstrated abnormalities in vascular and myocardial function of treatment-naive, early RA patients.2,3

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: biological DMARDs (bDMARDs), conventional DMARDs (csDMARDS), disease-modifying antirheumatic drug (DMARD), early RA, etanercept, Rheumatoid Arthritis (RA)

You Might Also Like:
  • Cardiovascular Abnormalities Seen in Treatment-Naive RA Patients
  • Effects of Obesity on Sustained Remission in Early RA
  • Higher Tocilizumab Dose Plus Methotrexate Best for Early RA
  • Insight into Endothelial Dysfunction in Early SLE Patients without Cardiovascular Disease

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.